Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Deferred Revenue data on file, last reported at $630000.0 in Q1 2026.

• Quarterly Current Deferred Revenue fell 98.14% year-over-year to $630000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $630000.0 (down 98.14% YoY) and the FY2025 annual result came in at $7.3 million, down 81.27% from the prior year.
• Current Deferred Revenue declined to $630000.0 in Q1 2026 per NTLA's latest filing, from $7.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $113.2 million in Q1 2022 and bottomed at $630000.0 in Q1 2026.
• The 5-year median for Current Deferred Revenue is $44.8 million (2024), against an average of $46.3 million.
• The widest annual swing landed in 2024, when Current Deferred Revenue surged 71.73%; it then tumbled 98.14% in 2026.
• Tracing NTLA's Current Deferred Revenue over 5 years: stood at $63.8 million in 2022, then declined by 4.36% to $61.0 million in 2023, then sank by 36.19% to $38.9 million in 2024, then plunged by 81.27% to $7.3 million in 2025, then slumped by 91.36% to $630000.0 in 2026.
• Per Business Quant, the three latest NTLA Current Deferred Revenue figures stand at $630000.0 (Q1 2026), $7.3 million (Q4 2025), and $12.2 million (Q3 2025).

Peer Comparison